FIELD: biotechnology.
SUBSTANCE: disclosed is a recombinant oncolytic herpes simplex virus (oHSV) containing a non-HSV ligand specific to a molecule (a protein, lipid or carbohydrate determinant) present on the cell surface (such as a cancer cell), and one or more copies of one or more target sequences of micro-RNAs built into one or more HSV gene loci, preferably into one or more HSV genes required for replication of HSV in normal (i.e. non-cancerous) cells.
EFFECT: invention can be used in medicine to kill tumor cells using oHSV.
50 cl, 10 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HERPES SIMPLEX SYNCYTIAL ONCOLYTIC MUTANTS AS POWERFUL THERAPEUTIC AGENTS FOR TREATING CANCER | 2020 |
|
RU2821999C2 |
| TREATING CANCER USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANIZED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2831418C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
| GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR-ASSOCIATED/SPECIFIC ANTIGEN | 2022 |
|
RU2827338C1 |
| UNNATURAL PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) AND METHODS OF APPLICATION | 2015 |
|
RU2687150C2 |
| COMPOSITIONS AND METHODS FOR DEGRADATION OF IMPROPERLY PACKAGED PROTEINS | 2016 |
|
RU2761564C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| MATERIALS AND METHODS USED FOR TREATMENT OF RESPIRATORY DISEASES IN DOGS | 2020 |
|
RU2811752C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
